Dermatologic adverse events associated with use of adjuvant lapatinib in combination with paclitaxel and trastuzumab for HER2-positive breast cancer: A case series analysis Journal Article

   

Authors:	Friedman, M. D.; Lacouture, M.; Dang, C.
Article Title:	Dermatologic adverse events associated with use of adjuvant lapatinib in combination with paclitaxel and trastuzumab for HER2-positive breast cancer: A case series analysis
Keywords:	survival; placebo; skin toxicity; rash; toxicity; management; therapy; lapatinib; presentation; adjuvant; clinical; factor receptor inhibitors; open-label; phase-3 trial; her2+
Journal Title:	Clinical Breast Cancer
Volume:	16
Issue:	3
ISSN:	1526-8209
Publisher:	Elsevier Inc.
Date Published:	2016-06-01
Start Page:	E69
End Page:	E74
Language:	English
ACCESSION:	WOS:000377401900009
DOI:	10.1016/j.clbc.2015.11.001
PROVIDER:	wos
PUBMED:	26707653
PMCID:	PMC5599140
Notes:	Article -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/94797